Relationship between molecular response and quality of life with bosutinib or imatinib for chronic myeloid leukemia

Patients with newly diagnosed chronic phase chronic myeloid leukemia (CP CML) can be effectively treated with tyrosine kinase inhibitors (TKIs) and achieve a lifespan similar to the general population. The success of TKIs, however, requires long-term and sometimes lifelong treatment; thus, patient-a...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Ann Hematol
Hauptverfasser: Brümmendorf, Tim H., Gambacorti-Passerini, Carlo, Bushmakin, Andrew G., Cappelleri, Joseph C., Viqueira, Andrea, Reisman, Arlene, Isfort, Susanne, Mamolo, Carla
Format: Artigo
Sprache:Inglês
Veröffentlicht: Springer Berlin Heidelberg 2020
Schlagworte:
Original Article
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC7237399/
https://ncbi.nlm.nih.gov/pubmed/32307568
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00277-020-04018-1
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge